Moreover, abnormal activation of FOXM1 also contributes to drug-resistance in cancers including ovarian cancer, breast cancer, prostate cancer, nasopharyngeal carcinoma, acute myeloid leukemia and colorectal cancer [36–41]. This evidence concerns the gene FOXM1 and breast carcinoma.